Results: Before the revision of the guideline for oncology drugs in April 2006 in Japan, >80% of end points supporting approval were response rate and overall survival (OS) was not frequent. After the revision of the guideline in Japan, using OS in pivotal clinical trials applied for approval increased to more than approximately one-third of oncology drugs, although trials with an end point of response rate decreased. Regarding drugs for major cancers including non-small-cell lung cancer, gastric cancer, colorectal cancer, and breast cancer, survival was used as an end point in 44.0%, whereas surrogate end points were used in 56.0%. Exploration of potential factors for using surrogate end points other than survival carried out through determinations of Annals of Oncology original articles odds ratios and 95% confidence intervals identified 'orphan drug designation in Japan' and 'accelerated approval by the U.S. Food and Drug Administration' as significant factors.
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency introduction The guideline of methods for the clinical evaluation of anticancer drugs issued in February 1991 represents the first regulation for the clinical development of anticancer drugs in Japan [1] . In the past, the regulatory agency would accept the results of phase 2 studies that mainly used a response rate as an end point in accordance with this guideline and grant approval for anticancer drugs. However, the guideline for anticancer drugs was revised [2] , and was implemented in April 2006. The revised guideline describes non-small-cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer (CRC), and breast cancer (BC) as examples of major cancers from which many patients suffer, and requires the results from phase 3 studies with life-prolonging effects, such as overall survival (OS) as an end point, to be submitted at the time of application, at least for drugs indicated for major cancers.
OS is the gold standard for a 'hard end point' in clinical studies in the area of oncology [3] . Not only the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, but also regulatory agencies in developed countries outside Japan, such as the Food and Drug Administration (FDA) in the USA and the European Medicines Agency (EMA), currently demand that OS is used as an end point for clinical pivotal studies to be included in the clinical data package at the time of New Drug Application (NDA) for approval of an oncology drug [4] [5] [6] . However, the problem with conducting a clinical study using OS is that the size of study is increased compared with a study using other end points, requiring a number of years until the study ends. Drug development is a long and costly process, typically taking 15 years and $1 billion to shepherd a drug through the initial discovery, clinical testing, and regulatory approval [7] . Inclusion of surrogate end points and shorter end points will ensure faster clinical trials in oncology and faster launch of drugs for cancer, and will therefore provide numerous benefit to patients.
There have been no studies on end points used in clinical studies supporting approval of oncology drugs in Japan. This study comprehensively investigated end points that have been used in pivotal clinical studies for the approval of oncology drugs in Japan, and examined factors that potentially influence the acceptance of surrogate end points as an approval condition set by the PMDA, the Japanese regulatory agency. 
data collection
Data were collected from the databases available to public in the PMDA website (http://www.pmda.go.jp/english/index.html). Each indication was counted for each drug, including indications approved at the same time, as long as substantive data with pivotal clinical trials for each indication. Documents were also used as references regarding drugs discussed in the special committee (http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_ iryou/iyakuhin/kaihatsuyousei/index.html; in Japanese), and drugs for the public knowledge-based application (http://www.mhlw.go.jp/bunya/iryouhoken/ topics/110202-01.html; in Japanese).
For end point evaluation, only one pivotal trial (the largest or most relevant trial) was considered for each indication. Additionally, when the primary study end point was multiple, and multiple end points met statistical criteria, the end point with highest priority was taken for this analysis, according to the following hierarchy: survival; symptom; time to event ( progression-free survival [PFS], time to progression, and time to recurrence); and response rate. For example, if OS did not show a significant difference for an approved drug, but PFS did, then the drug was regarded as approved on the basis of PFS. Response rates also included hematological response, in patients with hematologic malignancy. Information on the US Regulatory measures that applied to drugs for NDA review was collected from the FDA website (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/).
statistical methods
We used Fisher's exact test for a 2-by-2 contingency table to compare distributions of categorical attributes. To compare potential factors for using surrogate end points, we estimated the odds ratio (OR) and 95% confidence interval (CI). results historic use of different end points Table 1 summarizes end points that were used to support approval of oncology drugs in Japan before and after the guideline revision in April 2006. End points used to support approval were defined as those used in pivotal clinical trials conducted at the time of NDA. Before the revision of the guideline, >80% of end points to support approval were response rate. After the revision, survival increased to the most frequently used end point at 34.9%, followed by response rate at 33.7%. We defined end points other than survival as the surrogate end points. With a 2-by-2 table, we carried out comparison before and after the revision of the guideline, and found significant difference in using surrogate end points between before and after revision (P = 0.002, Fisher's exact test, supplementary Table S1 and Figure S1 , available at Annals of Oncology online).
oncology drugs after the revision of the guideline Drugs for cancer submitted for approval after 1 April 2006 (the day on which the revised guideline to methods for the clinical evaluation of anticancer drugs came into effect) were investigated in more detail. By 30 April 2014, a total of 55 drugs had been approved in Japan for 83 oncology indications (supplementary Table S2 and Figure S2 , available at Annals of Oncology online). Table 2 presents the results of aggregation of 83 indications. Of these indications, 31 were approved through the initial NDA (iNDA), and 52 through the supplemental NDA (sNDA). Of those in the iNDA, indications for sunitinib (renal cell carcinoma and gastrointestinal tumor) and dasatinib (chronic myelogenous leukemia and Philadelphia-positive acute lymphoblastic leukemia) were approved at the same time, so each drug was regarded as approved through two separate iNDAs. By mechanism of action, the largest number of indications was approved for molecularly targeted drugs, at ∼50%, followed by cytotoxic drugs at 42%. Drugs belonging to the other drugs were vaccines and radioactive agents. As for methods of application, the largest number of drugs went through priority review designation at 31.3%. Regarding types of development, bridging strategy accounted for >50%. Table 3 reports the cancer types of these 83 indications. NSCLC, GC, CRC, and BC, which were regarded as major cancers in the revised guideline, accounted for 30.1% of the whole. Indications with one or two drugs were classified as 'Other solid tumors' or 'Other hematologic malignancies' (supplementary Figure S3 , available at Annals of Oncology online).
end points used to support the approval of oncology drugs in Japan
We investigated the characteristics of drugs and indications approved through clinical studies that used survival as an end point supporting approval, and those approved through clinical studies that used surrogate as an end point. Variables include iNDA/sNDA, mode of action of drug, cancer type (major cancer/non-major cancer), special applications in Japan (orphan drugs, public knowledge-based application, priority review, and review meetings on unapproved/off-label drugs), limitation of indications, post-marketing commitment, developmental type, special applications for the FDA (fast track, priority review/orphan, accelerated approval, and breakthrough therapy designation), the FDA approval at approval in Japan, and trial size of pivotal clinical studies. Among drugs for major cancers, 44.0% were approved on the basis of studies that used survival as the end point, whereas 56.0% used surrogate end points. Fisher's exact test was carried out to evaluate whether survival was used as the end point in clinical studies involving patients with major cancers and other types of cancers. No significant difference was confirmed as a result (P = 0.318, Figure 1 ). ORs and 95% CIs were determined for each risk factor to evaluate whether surrogate end points were used instead of survival (Figure 1 ). Among the potential factors, 'orphan drug designation in Japan' and 'accelerated approval designation in FDA' were identified as factors leading to the use of surrogate end points, with the lower limit of CI >1 for both factors. In addition, 'priority review in Japan' and 'bridging strategy' were identified as factors leading to the use of OS, with the upper limit of CI <1 for both factors.
discussion
The previous Japanese guideline for oncology drugs stated that phase 3 trials needed to be conducted after approval and required only the protocol to be submitted at the time of approval. In fact, however, almost no phase 3 trials were conducted after approval in Japan [8] . Therefore, the revised guideline in 2006 requires results of phase 3 trials for survival benefits, especially in major cancers as mandatory. The purpose of this study is to examine what end point the PMDA has required for approval of oncology drugs after the revision of the guideline, and to identify potential factors of surrogate end points to be accepted by the PMDA. Our study showed that using OS in pivotal clinical trials applied for approval increased to more than approximately one-third of drugs after the revision of guideline in Japan, whereas trials with an end point of response rate decreased. On the other hand, about two-thirds of drugs were found to have been approved with surrogate end points instead of OS in clinical trials. More than half of drugs were approved on the basis of surrogate end points even for cancers classified as major cancers in the guideline.
We identified 'priority review designation in Japan' and 'bridging strategy' as factors leading to the use of OS on the basis of an upper limit of 95% CI of the OR <1. To interpret the result of 'priority designation', it is important to understand that the priority review designation in Japan is granted after the NDA. We assume that the PMDA tends to grant priority reviews for drugs for which results with a big impact are obtained from studies that use OS. 'Bridging strategy' was also a potential factor leading to the use of OS. Only two indications with paclitaxel (Taxol, BristolMyers Squibb, US) out of 47 indications with 'bridging strategy' in our study include Japanese patients in pivotal trials, although almost indications have no Japanese patients in pivotal trials. A revised guideline accepts the results of pivotal trials with OS conducted in abroad, because drugs can be provided to the Japanese patients efficiently and speedily [2] . We suppose that the extrapolation of robust OS data even outside Japan is acceptable to the PMDA. However, there is no significant difference on the use of OS between in simultaneous strategy with international trials including Japan and in other strategies. We found that international clinical trials in the 18 simultaneous strategies had generally been conducted with a larger sample size (average 921 patients), primary end points were 10 PFSs, 4 response rates, 3 OSs, and 1 DFS. We suppose that there was no significant and simple relationship between the use of OS and large scale trials. Also, there was no significant relationship between use of OS and participation of Japanese patients.
Potential factors of approvals based on surrogate end points were identified as 'orphan drug designation in Japan' and 'accelerated approval in FDA'. The reason for 'orphan drug' becoming a potential factor is probably attributable to the limitation in the size of clinical trials as well as in trial design owing to the rarity of the target disease, leading to inevitable situations where there is no other choice but to use surrogate end points. Furthermore, a report in the USA describes that, compared with drugs for non-orphan diseases, a larger number of oncology drugs have been granted an orphan drug designation by the FDA on the basis of clinical studies that used response rate as an end point instead of OS [9] . This result is consistent with our findings. The accelerated approval program is a system of the FDA that aims to promote the development of drugs for highly serious indications, and using surrogate end points is common under this program [10] . We considered that the correlation between accelerated approval and surrogate end points was Odds ratio --> Favor of surrogate Favor of survival<-- Figure 1 . Forest plot of the odds ratios (ORs) and 95% confidence intervals (CIs) of each potential factor that affect using surrogate end point or survival end point. To compare the distributions of categorical attributes between surrogate endpoints and survival endpoints supporting approval, Fisher's exact test for a 2-by-2 contingency table was used. To compare potential factors that may have potential correlation with using surrogate endpoints or survival endpoints, logistic regression models were adapted. From these models, the ORs and 95% CIs were estimated. The vertical lines indicate an OR of 1.0, values <1.0 favor survival as an end point, and values >1.0 favor surrogate end points. Plus sign represents the OR of each potential factor. The horizontal line represents the 95% CI and indicates that the CI extends beyond the scale of the plot. 
